Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

• DOI: 10.5505/aot.2023.41196
• Publication Date: 2023-08-07T06:26:03Z
• Authors: Cihan Erol; Emre Hafızoğlu; Musa Barış Aykan; Deniz Can Güven; Bengü Dursun; Mutlu Hızal; Seda Kahraman; Didem Şener Dede; Muhammed Bülent A...; Nuri Karadurmuş; Yüksel Ürün; Efnan Algın; Şuayib Yalçın; Bülent Yalçın; Mehmet Ali Nahit ...
• Keywords: FOLFIRINOX; Adjuvant Chemotherapy

Background: Pancreatic cancer is among the cancers with worst prognosis and therefore adjuvant treatment very important for reducing mortality.The aim of this study to compare gold standard mFolfirinox regimen other regimens in pancreatic real-world practice.Materials methods: Patients who underwent resection received at least one dose chemotherapy were included as two groups, Others (at a ratio 1:2).The primary endpoint was disease-free survival (DFS).Secondary endpoints determined overall (OS), predictive factors, safety.Results: Data 166 patients collected from five oncology centers.With median follow-up 30.3 months (24.6-35.9), estimated DFS detected 17.9 (95% CI, 10.3-25.6) group 12.5 9.7-15.3) others (p = 0.088).The OS 30.7 15.7-45.7) 22 16-27.9) (p=0.464).Better ECOG performance status, tumor location outside head ampulla, stage 1 2B, not receiving chemoradiotherapy (CRT), perineural invasion provide advantage favor mFolfirinox. Conclusion:In resected cancer, provided statistically insignificant, but clinically significant benefit.